Obesity is now one of the most serious health problems worldwide. It raises the risk of heart disease, type 2 diabetes, stroke, joint problems, and several kinds of cancer. Millions of people struggle with excess weight, and many find that diet and exercise alone are not enough to achieve lasting results.
Although some medicines are available, doctors still have limited options that are both safe and effective for severe obesity. This leaves many patients feeling frustrated and discouraged.
Researchers at Johns Hopkins Medicine have discovered a surprising new possibility. They have been studying a drug that was originally designed to treat conditions such as Alzheimer’s disease, schizophrenia, and sickle cell disease.
The drug did not succeed for those illnesses, but scientists noticed that it affects processes in the body linked to metabolism and heart function. This observation led them to wonder whether the medicine could help with obesity instead.
The drug works by blocking an enzyme called PDE9. Enzymes are proteins that speed up chemical reactions in the body and help control many biological processes. PDE9 influences how cells respond to signals that regulate blood flow, energy use, and fat storage.
When this enzyme is active, it can interfere with the body’s ability to burn fat efficiently. By blocking PDE9, the researchers hoped to improve how the body handles energy and fat.
In experiments with mice that were prone to obesity, the results were striking. Animals that received the drug gained less weight and had lower levels of body fat than those that did not receive it. The treated mice also showed improvements in fatty liver disease, a condition in which excess fat builds up in the liver and can lead to serious damage.
In addition, their heart function improved, and their blood pressure and blood sugar levels were better controlled. Most surprising was that these benefits occurred without the mice eating less food or becoming more active.
The idea to investigate PDE9 came from earlier work by the same research team in 2015. At that time, scientists found that this enzyme is active in the heart and can worsen heart problems, especially when blood pressure is high.
Since obesity often goes hand in hand with heart disease, the researchers suspected that blocking PDE9 might also help with weight‑related conditions. Their new study supports this idea and suggests that the enzyme plays a broader role in metabolism than previously understood.
The medicine tested in the study is known as a PDE9 inhibitor. It belongs to a family of drugs that work in a way similar to Viagra, which blocks a related enzyme called PDE5.
Both enzymes control a signaling molecule called cyclic GMP, which helps regulate blood vessel relaxation, energy balance, and other important body functions. By increasing cyclic GMP levels, PDE9 inhibitors may encourage the body to burn stored fat rather than accumulate it.
The specific drug used in the experiments, PF‑04447943, was developed by Pfizer. Although it did not succeed as a treatment for brain diseases, it was tested in more than 100 people during early clinical trials and was found to be safe, with no serious side effects.
This safety record makes it especially interesting as a possible future treatment for obesity, since developing a completely new drug from scratch can take many years.
Obesity rates continue to rise across the world. In the United States, for example, more than 40 percent of adults are considered obese, according to the Centers for Disease Control and Prevention.
Older adults are particularly affected, and obesity increases the risk of chronic illness and reduced quality of life. Because of this, new treatment options are urgently needed.
If the effects seen in mice also occur in humans, the impact could be dramatic. Researchers estimate that a person weighing 250 pounds might lose a significant amount of weight simply by taking a daily pill that blocks PDE9, without drastic lifestyle changes.
However, scientists emphasize that this possibility must be tested carefully in human trials before any conclusions can be made.
The study was led by researcher David Kass and published in the Journal of Clinical Investigation. The findings challenge the long‑held belief that obesity is caused only by overeating and lack of exercise. Instead, they suggest that biological factors such as enzymes and metabolic pathways also play an important role in how the body stores fat.
Although more research is needed, this discovery offers hope for a new approach to treating obesity. Future studies will determine whether PDE9 inhibitors can safely help people lose weight and improve overall health.
If successful, this once‑discarded drug could become a groundbreaking therapy, giving millions of people a new chance to manage their weight and reduce their risk of serious disease.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
